JP2000507456A - 拮抗的特性を有する血管内皮細胞増殖因子の変異体 - Google Patents
拮抗的特性を有する血管内皮細胞増殖因子の変異体Info
- Publication number
- JP2000507456A JP2000507456A JP10518674A JP51867498A JP2000507456A JP 2000507456 A JP2000507456 A JP 2000507456A JP 10518674 A JP10518674 A JP 10518674A JP 51867498 A JP51867498 A JP 51867498A JP 2000507456 A JP2000507456 A JP 2000507456A
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- amino acid
- antagonist
- sequence
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.変異体血管内皮増殖因子ポリペプチドを含むVEGFアンタゴニスト分子 であって、少なくとも1つのシステイン残基のアミノ酸修飾を含み、該アミノ酸 修飾が別の血管内皮増殖因子ポリペプチドモノマーと適切に二量体化する能力を 阻害し、該アンタゴニスト分子が血管内皮増殖因子応答を有意に誘導することな く血管内皮増殖因子レセプターと結合することができるアンタゴニスト分子、お よび該アンタゴニスト分子の機能的誘導体。 2.該アミノ酸修飾が、該少なくとも1つのシステイン残基の、ジスルフィド 結合にあずかることのできない異なったアミノ酸による置換である、請求項1記 載のアンタゴニスト分子。 3.該置換が、天然VEGFアミノ酸配列の第51位および/または第60位 アミノ酸のシステイン残基の置換である、請求項2記載のアンタゴニスト分子。 4.システインがアスパラギン酸で置換されている、請求項3記載のアンタゴ ニスト分子。 5.置換C51Dを含む請求項4記載のアンタゴニスト分子。 6.置換C60Dを含む請求項4記載のアンタゴニスト分子。 7.該アミノ酸修飾が、該システイン残基をジスルフィド結合にあずかること ができないようにする該少なくとも1つのシステイン残基の化学修飾である、請 求項1記載のアンタゴニスト分子。 8.該化学修飾が、天然VEGFアミノ酸配列の第51位および/または第6 0位アミノ酸の化学修飾である、請求項7記載のアンタゴニスト分子。 9.それ以外には本質的な生物学的性質に影響を及ぼさないアミノ酸修飾をさ らに含む、請求項1記載のアンタゴニスト分子。 10.請求項1記載のVEGFアンタゴニスト分子をコードする配列を含む、 単離された核酸配列。 11.形質転換体宿主細胞中で請求項10記載の核酸を発現することが可能な 複製可能な発現ベクター。 12.請求項11記載のベクターで形質転換された宿主細胞。 13.チャイニーズハムスター卵巣細胞である、請求項12記載の宿主細胞。 14.薬学的に許容し得る担体と混合した請求項1記載のVEGFアンタゴニ スト分子を含む物質の組成物。 15.請求項14記載の組成物を投与することを含む治療方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/734,443 US6750044B1 (en) | 1996-10-17 | 1996-10-17 | Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids |
US08/734,443 | 1996-10-17 | ||
PCT/US1997/019471 WO1998016551A2 (en) | 1996-10-17 | 1997-10-10 | Variants of vascular endothelial cell growth factor having antagonistic properties |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004207942A Division JP2004339233A (ja) | 1996-10-17 | 2004-07-14 | 拮抗的特性を有する血管内皮細胞増殖因子の変異体 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000507456A true JP2000507456A (ja) | 2000-06-20 |
Family
ID=24951725
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10518674A Withdrawn JP2000507456A (ja) | 1996-10-17 | 1997-10-10 | 拮抗的特性を有する血管内皮細胞増殖因子の変異体 |
JP2004207942A Pending JP2004339233A (ja) | 1996-10-17 | 2004-07-14 | 拮抗的特性を有する血管内皮細胞増殖因子の変異体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004207942A Pending JP2004339233A (ja) | 1996-10-17 | 2004-07-14 | 拮抗的特性を有する血管内皮細胞増殖因子の変異体 |
Country Status (11)
Country | Link |
---|---|
US (3) | US6750044B1 (ja) |
EP (1) | EP0931092B1 (ja) |
JP (2) | JP2000507456A (ja) |
AT (1) | ATE257485T1 (ja) |
AU (1) | AU718327B2 (ja) |
CA (1) | CA2267661C (ja) |
DE (1) | DE69727149T2 (ja) |
DK (1) | DK0931092T3 (ja) |
ES (1) | ES2214640T3 (ja) |
PT (1) | PT931092E (ja) |
WO (1) | WO1998016551A2 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005502333A (ja) * | 2001-08-01 | 2005-01-27 | ユニバーシティ オブ ブリストル | 増殖因子イソ型 |
JP2009511492A (ja) * | 2005-10-06 | 2009-03-19 | トロフォゲン,インコーポレイテッド | Vegf類縁体および使用方法 |
US10457713B2 (en) | 2012-07-30 | 2019-10-29 | Trophogen, Inc. | Glycoprotein hormone long-acting superagonists |
US10544200B2 (en) | 2013-11-05 | 2020-01-28 | Trophogen, Inc. | Glycoprotein hormone long-acting superagonists |
US10766941B2 (en) | 2012-07-30 | 2020-09-08 | Trophogen Inc. | Glycoprotein hormone long-acting superagonists |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6020473A (en) * | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
DK1140173T4 (da) * | 1998-12-22 | 2013-06-10 | Genentech Inc | Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf |
US6783953B1 (en) | 1998-12-22 | 2004-08-31 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-X |
ES2265931T3 (es) * | 1999-04-16 | 2007-03-01 | Genentech, Inc. | Variantes del factor de crecimiento celular endotelial vascular (vegf) y sus usos. |
US7090834B1 (en) | 1999-04-16 | 2006-08-15 | Genentech, Inc. | Vascular endothelial cell growth factor variants and uses thereof |
WO2000071713A1 (en) * | 1999-05-20 | 2000-11-30 | Scios Inc. | Vascular endothelial growth factor variants |
AU6600400A (en) * | 1999-08-13 | 2001-03-13 | Crucell Holland B.V. | Methods and means for inhibiting angiogenesis |
IL148674A0 (en) * | 1999-11-02 | 2002-09-12 | Genentech Inc | Modulation of enos activity and therapeutic uses thereof |
US7078382B1 (en) | 1999-11-02 | 2006-07-18 | Genentech, Inc. | Modulation of eNOS activity and therapeutic uses thereof |
US7355019B2 (en) * | 2000-06-06 | 2008-04-08 | Sibtech, Inc. | Cysteine-containing peptide tag for site-specific conjugation of proteins |
AU2002338313A1 (en) * | 2001-04-06 | 2002-10-21 | Maxygen Holdings Ltd. | Single chain dimeric polypeptides derived from the vegf family |
WO2003002609A2 (en) * | 2001-06-28 | 2003-01-09 | Domantis Limited | Dual-specific ligand and its use |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
CN1678634A (zh) * | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
DK1537146T3 (da) | 2002-07-15 | 2011-04-04 | Univ Texas | Antistoffer, der binder til anioniske phospholipider og aminophospholipider, og deres anvendelse til behandling af virusinfektioner |
EP1578801A2 (en) * | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
PT1639013E (pt) | 2003-07-02 | 2012-12-03 | Innate Pharma | Anticorpos contra receptor nk pan-kir2dl e a sua utilização em diagnóstico e terapêutica |
US20090191213A9 (en) | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
AU2005259221B2 (en) | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
JP5130044B2 (ja) | 2004-08-03 | 2013-01-30 | イナート・ファルマ | 4ig−b7−h3およびその対応するnk細胞受容体を標的化する治療および診断方法ならびに組成物 |
EP1831258B2 (en) | 2004-12-28 | 2023-06-07 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
ATE531733T1 (de) | 2005-01-06 | 2011-11-15 | Novo Nordisk As | Kir-bindende wirkstoffe und verfahren zu ihrer verwendung |
US7893244B2 (en) * | 2005-04-12 | 2011-02-22 | Intradigm Corporation | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases |
JP2008537752A (ja) * | 2005-04-12 | 2008-09-25 | イントラディグム コーポレイション | がんおよび他の新血管形成疾患を処置するためのRNAi治療用の組成物および方法 |
BRPI0619225A2 (pt) * | 2005-12-01 | 2017-11-07 | Domantis Ltd | monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória |
US20080032343A1 (en) | 2005-12-22 | 2008-02-07 | Genentech, Inc. | Recombinant Production of Heparin Binding Proteins |
ZA200900229B (en) | 2006-07-14 | 2010-04-28 | Genentech Inc | Refolding of recombinant proteins |
WO2008011513A2 (en) | 2006-07-19 | 2008-01-24 | The Cleveland Clinic Foundation | Compounds and methods of modulating angiogenesis |
TWI541251B (zh) * | 2006-10-04 | 2016-07-11 | 建南德克公司 | 用於vegf之elisa |
EP2083830A1 (en) | 2006-11-17 | 2009-08-05 | Innate Pharma | Improved methods of using phosphoantigen for the treatment of cancer |
EP2136831B1 (en) | 2007-03-02 | 2012-09-12 | The Cleveland Clinic Foundation | Anti-angiogenic peptides |
BRPI0812398A2 (pt) * | 2007-06-06 | 2019-09-24 | Domantis Ltd | domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão |
MX2010005104A (es) | 2007-11-09 | 2010-08-04 | Peregrine Pharmaceuticals Inc | Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos. |
AU2009274512A1 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of Colorado | Clip inhibitors and methods of modulating immune function |
EP3216458A1 (en) | 2016-03-07 | 2017-09-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Modified vascular endothelial growth factor a (vegf-a) and its medical use |
US10786471B2 (en) | 2017-02-06 | 2020-09-29 | Massachusetts Institute Of Technology | Methods and products related to glutaminase inhibitors |
WO2019211492A1 (en) | 2018-05-04 | 2019-11-07 | Tollys | Tlr3 ligands that activate both epithelial and myeloid cells |
CN114606240B (zh) * | 2022-03-15 | 2023-05-09 | 暨南大学 | 特异性识别血管内皮生长因子的核酸适配体及用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456550A (en) | 1982-11-22 | 1984-06-26 | President And Fellows Of Harvard College | Vascular permeability factor |
US5008196A (en) | 1987-08-21 | 1991-04-16 | Monsanto Company | Stimulation of endothelial cell growth |
US5036003A (en) | 1987-08-21 | 1991-07-30 | Monsanto Company | Antibodies to VPF |
US5008195A (en) * | 1988-08-05 | 1991-04-16 | Uop | Some novel producers of cyclodextrin glycosyltransferases |
US5240848A (en) | 1988-11-21 | 1993-08-31 | Monsanto Company | Dna sequences encoding human vascular permeability factor having 189 amino acids |
US5219739A (en) * | 1989-07-27 | 1993-06-15 | Scios Nova Inc. | DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121 |
JPH06503966A (ja) * | 1990-12-21 | 1994-05-12 | クリエイティブ バイオモレキュルズ インコーポレイテッド | 生合成したpdgfアンタゴニスト |
EP0536350B1 (en) | 1991-02-22 | 2002-08-07 | American Cyanamid Company | Identification of a novel human receptor tyrosine kinase gene |
US5185438A (en) | 1991-04-02 | 1993-02-09 | The Trustees Of Princeton University | Nucleic acids encoding hencatoporetic stem cell receptor flk-2 |
CN1173991C (zh) | 1992-11-13 | 2004-11-03 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k-1 |
CA2158745C (en) | 1993-03-25 | 2007-06-19 | Richard L. Kendall | Inhibitor of vascular endothelial cell growth factor |
GB9410534D0 (en) | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
US6020473A (en) * | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
-
1996
- 1996-10-17 US US08/734,443 patent/US6750044B1/en not_active Expired - Lifetime
-
1997
- 1997-10-10 EP EP97946328A patent/EP0931092B1/en not_active Expired - Lifetime
- 1997-10-10 WO PCT/US1997/019471 patent/WO1998016551A2/en active IP Right Grant
- 1997-10-10 ES ES97946328T patent/ES2214640T3/es not_active Expired - Lifetime
- 1997-10-10 DK DK97946328T patent/DK0931092T3/da active
- 1997-10-10 AU AU51523/98A patent/AU718327B2/en not_active Expired
- 1997-10-10 PT PT97946328T patent/PT931092E/pt unknown
- 1997-10-10 AT AT97946328T patent/ATE257485T1/de active
- 1997-10-10 CA CA002267661A patent/CA2267661C/en not_active Expired - Lifetime
- 1997-10-10 DE DE69727149T patent/DE69727149T2/de not_active Expired - Lifetime
- 1997-10-10 JP JP10518674A patent/JP2000507456A/ja not_active Withdrawn
-
2004
- 2004-03-03 US US10/793,094 patent/US20040152636A1/en not_active Abandoned
- 2004-07-14 JP JP2004207942A patent/JP2004339233A/ja active Pending
-
2006
- 2006-09-28 US US11/536,547 patent/US20070238659A1/en not_active Abandoned
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005502333A (ja) * | 2001-08-01 | 2005-01-27 | ユニバーシティ オブ ブリストル | 増殖因子イソ型 |
JP2010100626A (ja) * | 2001-08-01 | 2010-05-06 | Univ Of Bristol | 増殖因子イソ型 |
JP4689956B2 (ja) * | 2001-08-01 | 2011-06-01 | ユニバーシティ オブ ブリストル | 増殖因子イソ型 |
JP2009511492A (ja) * | 2005-10-06 | 2009-03-19 | トロフォゲン,インコーポレイテッド | Vegf類縁体および使用方法 |
JP2013177458A (ja) * | 2005-10-06 | 2013-09-09 | Trophogen Inc | Vegf類縁体および使用方法 |
US9078860B2 (en) | 2005-10-06 | 2015-07-14 | Trophogen, Inc. | VEGF analogs |
US10457713B2 (en) | 2012-07-30 | 2019-10-29 | Trophogen, Inc. | Glycoprotein hormone long-acting superagonists |
US10766941B2 (en) | 2012-07-30 | 2020-09-08 | Trophogen Inc. | Glycoprotein hormone long-acting superagonists |
US10544200B2 (en) | 2013-11-05 | 2020-01-28 | Trophogen, Inc. | Glycoprotein hormone long-acting superagonists |
Also Published As
Publication number | Publication date |
---|---|
US20070238659A1 (en) | 2007-10-11 |
AU718327B2 (en) | 2000-04-13 |
CA2267661C (en) | 2005-08-23 |
ATE257485T1 (de) | 2004-01-15 |
JP2004339233A (ja) | 2004-12-02 |
PT931092E (pt) | 2004-05-31 |
EP0931092B1 (en) | 2004-01-07 |
WO1998016551A3 (en) | 1998-05-28 |
AU5152398A (en) | 1998-05-11 |
WO1998016551A2 (en) | 1998-04-23 |
US6750044B1 (en) | 2004-06-15 |
DE69727149T2 (de) | 2004-10-28 |
EP0931092A2 (en) | 1999-07-28 |
DE69727149D1 (de) | 2004-02-12 |
DK0931092T3 (da) | 2004-05-17 |
ES2214640T3 (es) | 2004-09-16 |
US20040152636A1 (en) | 2004-08-05 |
CA2267661A1 (en) | 1998-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000507456A (ja) | 拮抗的特性を有する血管内皮細胞増殖因子の変異体 | |
JP3117992B2 (ja) | 血管内皮細胞成長因子の生産およびそれをコードするdna | |
JPH10511557A (ja) | 血管内皮細胞増殖因子の変種、それらの使用およびそれらの生産法 | |
US9078860B2 (en) | VEGF analogs | |
JP4741139B2 (ja) | 可溶性インターロイキン−20レセプター | |
US6391311B1 (en) | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 | |
JP7403595B2 (ja) | 新規なヒト血清アルブミン変異体 | |
JP2002523036A (ja) | イムノフュージンとしての新脈管形成インヒビターの発現および輸送 | |
US20100197575A1 (en) | Soluble interleukin-20 receptor | |
CA2370246C (en) | Vascular endothelial cell growth factor variants and uses thereof | |
JP2018535964A (ja) | 線維芽細胞増殖因子(fgf)1アナログによるステロイド誘導性高血糖の処置 | |
JPWO2007122975A1 (ja) | Hgf前駆体蛋白質改変体及びその活性型蛋白質 | |
US7005505B1 (en) | Variants of vascular endothelial cell growth factor | |
JPH11500904A (ja) | Mplリガンド類似体 | |
US10968267B2 (en) | Serum albumin-20K growth hormone fusion protein | |
JP2004194665A (ja) | 血管内皮細胞増殖因子の変異体 | |
JP2001515719A (ja) | Mplリガンド類似体 | |
WO2023108666A1 (zh) | 一类靶向covid-19病毒s蛋白的超高亲和力小蛋白及用途 | |
JPH1156378A (ja) | 変異型ヒト成長ホルモンとその用途 | |
RO118299B1 (ro) | Polipeptida trombopoietina, secventa adn care o codifica, procedeu pentru prepararea polipeptidei trombopoietine si compozitie farmaceutica cu aceasta | |
JP3635142B2 (ja) | 抗tpo抗体の作製方法 | |
JPH1080277A (ja) | 変異型ヒト成長ホルモンとその用途 | |
KR20100085879A (ko) | 변형된 인간 트롬보포이에틴 폴리펩타이드 절편 및 그의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040316 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20040528 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20040528 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040714 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20040913 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20040913 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20040913 |